|
Market Closed -
Deutsche Boerse AG
15:41:56 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 3.202 EUR | -3.44% |
|
-3.90% | -41.36% |
| 09-02 | Evotec, Plectonic Launch Research Collaboration on New T-Cell Approaches for Solid Tumors | MT |
| 09-02 | Evotec, Plectonic Biotech Partner on Research of Novel Immunotherapy for Solid Tumors | MT |
Company Valuation: Evotec SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 7,444 | 2,696 | 3,765 | 1,453 | 966.4 | 570.9 | - | - |
| Change | - | -63.78% | 39.63% | -61.41% | -33.49% | -40.92% | - | - |
| Enterprise Value (EV) 1 | 7,099 | 2,485 | 3,787 | 1,669 | 938.7 | 713.8 | 733.1 | 744.1 |
| Change | - | -65% | 52.43% | -55.93% | -43.75% | -23.96% | 2.71% | 1.51% |
| P/E | 32.7x | -15.4x | -45.3x | -7.38x | -9.4x | -2.74x | -7.47x | -169x |
| PBR | 5.44x | 2.27x | 3.37x | 6.89x | 1.19x | 0.89x | 1.08x | 1.1x |
| PEG | - | 0x | 0.9x | -0x | 0.2x | -0x | 0.1x | 1.8x |
| Capitalization / Revenue | 12x | 3.59x | 4.82x | 1.82x | 1.23x | 0.95x | 0.79x | 0.73x |
| EV / Revenue | 11.5x | 3.31x | 4.85x | 2.09x | 1.19x | 1.19x | 1.01x | 0.95x |
| EV / EBITDA | 66.2x | 24.4x | 57.1x | 74x | 22.8x | -11.1x | 15.5x | 7.86x |
| EV / EBIT | 173x | 119x | -142x | -11.7x | -16.7x | -2.95x | -24.5x | 28.6x |
| EV / FCF | 2,155x | 114x | -21.4x | -16.8x | -11.5x | -4.19x | -12.9x | 100x |
| FCF Yield | 0.05% | 0.88% | -4.67% | -5.95% | -8.71% | -23.9% | -7.77% | 1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.3 | -0.99 | -0.47 | -1.11 | -0.58 | -1.174 | -0.4303 | -0.019 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 618 | 751.4 | 781.4 | 797 | 788.4 | 600.9 | 724.1 | 784.8 |
| EBITDA 1 | 107.3 | 101.7 | 66.35 | 22.56 | 41.1 | -64.22 | 47.3 | 94.62 |
| EBIT 1 | 41 | 20.85 | -26.63 | -142.5 | -56.2 | -242.1 | -29.88 | 25.99 |
| Net income 1 | 215.5 | -175.7 | -83.91 | -196.1 | -103.5 | -202 | -48.25 | 14.39 |
| Net Debt 1 | -345.3 | -211.8 | 22.09 | 216 | -27.66 | 142.8 | 162.2 | 173.2 |
| Reference price 2 | 42.500 | 15.260 | 21.280 | 8.195 | 5.450 | 3.212 | 3.212 | 3.212 |
| Nbr of stocks (in thousands) | 175,162 | 176,703 | 176,936 | 177,303 | 177,323 | 177,749 | - | - |
| Announcement Date | 4/12/22 | 5/12/23 | 4/24/24 | 4/17/25 | 4/8/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.15x | 5.95x | 17.82x | 0.98% | 48.93B | |
| -21.5x | 245.64x | -23.19x | -.--% | 45.01B | |
| 34.48x | 3.33x | 14.35x | -.--% | 44.07B | |
| 46.93x | 5.41x | 29.72x | -.--% | 40.73B | |
| 28.42x | 8.6x | 21.8x | 0.4% | 33.52B | |
| 33.62x | 5.51x | 25.02x | -.--% | 16.5B | |
| 24.24x | 2.11x | 9.11x | 1.11% | 14.67B | |
| 77.18x | 4.06x | 15.75x | -.--% | 13.77B | |
| Average | 32.07x | 35.07x | 13.80x | 0.31% | 32.15B | |
| Weighted average by Cap. | 27.26x | 47.36x | 12.31x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- EVT Stock
- EVT Stock
- Valuation Evotec SE
Select your edition
All financial news and data tailored to specific country editions
